Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA/CD19 Dual-Target CAR-T in R/R Multiple Myeloma
NCT04412889Phase 1Unknown
- Sponsor
- Lu Daopei Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA/CD19 dual-target CAR-T cell immunotherapy (Hebei Yanda Ludaopei Hospital) in multiple myeloma (MM), sponsored by Lu Daopei Hospital. Primary endpoints: Dose-Limiting Toxicity at 2 years, Adverse Events at 2 years and 2 more. Status: unknown.
02
Drugs
BCMA/CD19 dual-target CAR-T cell immunotherapy (Hebei Yanda Ludaopei Hospital)
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04412889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412889.